Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 463-467

  Jorgensen L G M ^a,b   Osterlind K ^c   Genolla J ^d   Gomm, S A ^e,f   Hernandez J R ^g   Johnson, P W M ^h,i   Lober J ^j   Splinter, T A W ^k   Szturmowicz, M ^l  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d HOSPITAL DE CRUCES   (Spain)

^e St Ann's Hospice   (United Kingdom)

^f WYTHENSHAWE HOSPITAL   (United Kingdom)

^g HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^j BISPEBJERG HOSPITAL   (Denmark)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l Inst of TB Pulmonary Diseases   (Poland)

more..

Author keywords

Neuron specific enolase; Prognostic factors; Small cell lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE;

ADULT; AGED; ALGORITHM; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030016693     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.383     Document Type: Article

References (24)

1. AKOUN GM, SCARNA HM, MILLERON BJ, BÉNICHOU MP AND HERMAN DP. (1985). Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest, 87, 39-43.
2. CARNEY DN, MARANGOS PJ, IHDE DC, BUNN PJ, COHEN MN AND MINNA JD. (1982). Serum neuron-specific enolase: a marker for disease extent and response to therapy of small cell lung cancer. Lancet, 1, 583-585.
3. CERNY T, BLAIR V, ANDERSON H, BRAMWELL V AND THATCHER N. (1987). Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int. J. Cancer, 39, 146-149.
4. COHEN MH, IHDE DC, BUNN PA, FOSSIECK BE Jr, MATTHEWS MJ Jr, SHACKNEY SE, JOHNSTON-EARLY A, MAKUCH R AND MINNA JD. (1979). Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat. Rep., 63, 163-170.
5. COHEN MH, MAKUCH R, JOHNSTON-EARLY A, IHDE DC, BUNN PA, FOSSIECK BE Jr AND MINNA JD. (1981). Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat. Rep., 65, 187-195.
6. COOPER EH, SPLINTER TAW, BROWN DA, MUERS MF, PEAKE MD AND PEARSON SL. (1985). Evaluation of a radioimmunoassay for neuron-specific enolase in small-cell lung cancer. Br. J. Cancer, 52, 333-338.
7. COX DR. (1972). Regression models and life-tables. J. R. Stat. Soc., 34, 187-220.
8. EDMONSON JH, LAGAKOS SW, SELAWRY OS, PERLIA CP, BENNETT JM AND MUGGIA FM. (1976). Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat. Rep., 60, 925-932.
9. GOMM SA, KEEVIL BG, THATCHER N, HASTLETON PS AND SWINDELL RS. (1988). The value of tumour markers in lung cancer. Br. J. Cancer, 58, 797-804.
10. HARDING M, MCALLISTER, HULKS G, VERNON D, MONIE R, PAUL J AND KAYE SB. (1990). Neuron-specific enolase (NSE) in small-cell lung cancer: a tumour marker of prognostic significance? Br. J. Cancer, 61, 605-607.
11. IHDE DC, MAKUCH RW, CARNEY DN, BUNN PA, COHEN MH, MATTHEWS MJ AND MINNA JD. (1981). Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am. Rev. Respir. Dis., 123, 500-507.
12. JOHNSON PWM, JOEL SP, LOVE S, BUTCHER M, PANDIAN MR, SQUIRES L, WRIGLEY PFM AND SLEVIN ML. (1993). Tumour markers for prediction of survival and monitoring of remission in small-cell lung cancer. Br. J. Cancer, 67, 760-766.
13. JØRGENSEN LGM, ØSTERLIND K, HANSEN HH AND COOPER EH. (1988). The prognostic influence of neuron-specific enolase in small-cell lung cancer. Br. J. Cancer, 58, 805-807.
14. KAPLAN E AND MEIER P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
15. KALBFLEISCH JD AND PRENTICE RL. (1980). The Statistical Analysis of Failure Time Data. John Wiley: New York.
16. KARNOFSKY DA AND BURCHENAL JH. (1949). The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of Chemotherapeutic Agents, MacLeod CM (ed.) p. 191. Columbia University Press: New York.
17. ØSTERLIND K AND ANDERSEN PK. (1986). Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res., 46, 4189-4194.
18. PARMAR MKB AND MACHIN D. (1995). Survival analysis. A practical approach. John Wiley: Chichester, UK.
19. RAWSON NSB AND PETO J. (1990). An overview of prognostic factors in small-cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br. J. Cancer, 61, 597-604.
20. SIMON R AND ALTMAN DG. (1994). Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer, 69, 979-985.
21. SOUHAMI RL, BRADBURY I, GEDDES DM, SPIRO SG, HARPER PG AND TOBIAS JS. (1985). Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res., 45, 2878-2882.
22. VINCENT MD, ASHLEY SE AND SMITH IE. (1987). Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur. J. Cancer Clin. Oncol., 23, 1589-1599.
23. WORLD HEALTH ORGANIZATION. (1982). Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva.
24. WOLF M, HOLLE R, HANS K, DRINGS P AND HAVEMANN K. (1991). Analysis of prognostic factors in 766 patients with small-cell lung cancer (SCLC): the role of sex as a predictor for survival. Br. J. Cancer, 63, 986-992.